1. Home
  2. TGB vs RARE Comparison

TGB vs RARE Comparison

Compare TGB & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taseko Mines Ltd.

TGB

Taseko Mines Ltd.

HOLD

Current Price

$6.76

Market Cap

2.1B

ML Signal

HOLD

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

HOLD

Current Price

$22.88

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGB
RARE
Founded
1966
2010
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
2002
2013

Fundamental Metrics

Financial Performance
Metric
TGB
RARE
Price
$6.76
$22.88
Analyst Decision
Hold
Strong Buy
Analyst Count
1
19
Target Price
$5.00
$59.32
AVG Volume (30 Days)
5.0M
2.0M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.31
EPS
N/A
N/A
Revenue
N/A
$673,000,000.00
Revenue This Year
$67.93
$13.12
Revenue Next Year
$24.16
$42.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
20.13
52 Week Low
$1.67
$18.29
52 Week High
$9.25
$40.17

Technical Indicators

Market Signals
Indicator
TGB
RARE
Relative Strength Index (RSI) 50.59 58.74
Support Level $5.36 $22.00
Resistance Level $9.08 $23.44
Average True Range (ATR) 0.35 0.95
MACD 0.11 0.38
Stochastic Oscillator 89.86 98.29

Price Performance

Historical Comparison
TGB
RARE

About TGB Taseko Mines Ltd.

Taseko Mines Ltd is a copper-focused mining company engaged in acquiring, developing, and operating large tonnage mineral deposits in stable jurisdictions that are capable of supporting a mine. Its principal assets are the wholly-owned Gibraltar mine (Gibraltar), which is located in central British Columbia (BC), and the Florence Copper mine, located in Arizona. Taseko also owns the Yellowhead copper, New Prosperity copper-gold, and Aley niobium projects in British Columbia, Canada.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: